Fig. 5From: Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapySwimmer plots of patients. Patients who received anlotinib plus oxaliplatin and capecitabine as first-line therapy in RAS/BRAF wild-type unresectable mCRCBack to article page